

**REMARKS**

Claims 1-6, 9, 10 and 17-23 are pending. Claims 7, 8, and 11-16 were previously canceled. Amendment of claims herein is made without abandonment of the original subject matter; Applicants reserve the right to pursue claims of the original or similar scope in a duly filed continuing application. Applicants respectfully request entry of the present amendment along with the amendment filed on June 13, 2005.


Claim 1 has been amended to recite "[a]n attenuated *Salmonella* strain comprising a eukaryotic expression vector comprising a eukaryotic promoter and a nucleic acid encoding a polypeptide, wherein said nucleic acid is under the control of said eukaryotic promoter, wherein the attenuation is suitable for administration to a vertebrate, and wherein administration to said vertebrate with said attenuated *Salmonella* strain results in expression of said polypeptide by said vertebrate and generates a response by said vertebrate to said polypeptide." Support for the amendment to claim 1 is found throughout the specification and at page 1, lines 9-11; page 5, lines 16-17, and line 27 through page 8; and page 11, line 16 through page 14 of the application as originally filed. Thus, the claim amendments herein find basis in the original specification and no new matter has been introduced.

**CONCLUSION**

For the reasons set out in the amendment filed on June 13, 2005, each of claims 1-6, 9, 10 and 17-23 is believed to be in condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejections of the claims and to pass this application to issue.

Dated: July 11, 2005

Respectfully submitted,

By 

Lynn L. Janulis

Registration No.: 53,066

Agent for Applicants

MARSHALL, GERSTEIN & BORUN, LLP  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606  
Telephone: (312) 474-6300